![[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!](https://businessfortnight.com/wp-content/uploads/2025/10/Toyota-Times-Century-as-a-Brand-Lexus-as-Innovation-All-218x150.jpg "[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!")
ORION CORPORATION
STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE
26 OCTOBER 2022 at 10.00 EEST
83,587 Orion Corporation A shares converted into B shares
In accordance with Section 3 of the Articles of Association of Orion Corporation, 83,587 A shares have been converted into 83,587 B shares. The conversion has been entered into the Trade Register on 26 October 2022.
The complete variety of shares in Orion Corporation is 141,134,278 which, after the conversion, consists of 34,226,937 A shares and 106,907,341 B shares. The variety of votes of the corporate’s shares is after the conversion 791,446,081.
Orion Corporation
| Jari Karlson
CFO |
Olli Huotari
SVP, Corporate Functions |
Contact individual:
Tuukka Hirvonen, Investor Relations, tel. +358 10 426 2721
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
www.orion.fi
Orion is a globally working Finnish pharmaceutical firm – a builder of well-being. Orion develops, manufactures and markets human and veterinary prescribed drugs and energetic pharmaceutical elements. The firm is constantly growing new medicine and therapy strategies. The core remedy areas of Orion’s pharmaceutical R&D are oncology and ache. Orion’s internet gross sales in 2021 amounted to EUR 1,041 million and the corporate had about 3,350 staff on the finish of the yr. Orion’s A and B shares are listed on Nasdaq Helsinki.
